Biotech stocks were starved for love on Wall Street in recent years, notwithstanding revolutionary research and the launch of novel therapies for once incurable diseases.
Not anymore. The catastrophic outbreak of Covid-19 has led to a reappraisal of the sector, even if viable treatments and vaccines seem far off. Sure, biotech stocks tanked this past month, but the iShares Nasdaq Biotechnology exchange-traded fund and other industry benchmarks have been outperforming the broader market.
What are the odds I click this and see $GILD just be honest
Abbiamo riassunto questa notizia in modo che tu possa leggerla velocemente. Se sei interessato alla notizia puoi leggere il testo completo qui. Leggi di più: